Literature DB >> 12603635

Migraine preventive medication reduces resource utilization.

Stephen D Silberstein1, Paul K Winner, Joseph J Chmiel.   

Abstract

OBJECTIVE: To determine if long-term resource utilization is reduced by adding a preventive medication to a migraine management regimen that already includes acute medication.
BACKGROUND: In 2000, new evidence-based guidelines for the treatment of migraine were released by the US Headache Consortium and the American Academy of Neurology. Although these guidelines emphasize the role of preventive medication in achieving significant clinical improvement, little yet is known concerning the impact of such management on medical and pharmaceutical resources. Methods.-Resource utilization information in a large claims database was analyzed retrospectively.
RESULTS: Adding a preventive medication to migraine management reduced the use of other migraine medications, as well as visits to physician offices and emergency departments. In addition, both acute and preventive medications were associated with lower utilization of computed tomography and magnetic resonance imaging scans.
CONCLUSION: Migraine preventive drug therapy is effective in reducing resource consumption when added to therapy consisting only of an acute medication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12603635     DOI: 10.1046/j.1526-4610.2003.03040.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  15 in total

Review 1.  Burden of tension-type headache.

Authors:  Marc E Lenaerts
Journal:  Curr Pain Headache Rep       Date:  2006-12

Review 2.  Prophylactic Treatment of Migraine.

Authors:  Azize Esra Gürsoy; Mustafa Ertaş
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

3.  Prophylactic treatment of migraine by GPs: a qualitative study.

Authors:  Frans Dekker; Arie Knuistingh Neven; Boukje Andriesse; David Kernick; Michel D Ferrari; Willem J J Assendelft
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

Review 4.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 5.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

Review 6.  Preventive Migraine Treatment.

Authors:  Stephen D Silberstein
Journal:  Continuum (Minneap Minn)       Date:  2015-08

Review 7.  The effect of migraine prophylaxis on migraine-related resource use and productivity.

Authors:  Miguel J A Láinez
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

8.  Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine.

Authors:  Kobina K Hagan; Wenyuan Li; Elizabeth Mostofsky; Suzanne M Bertisch; Angeliki Vgontzas; Catherine Buettner; Murray A Mittleman
Journal:  Headache       Date:  2020-12-21       Impact factor: 5.887

9.  Topiramate: the evidence for its therapeutic value in the prevention of migraine.

Authors:  Carole Nadin
Journal:  Core Evid       Date:  2005-06-30

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.